Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
2009
Estimating the reproducibility of psychological science
2015 StandoutScience
Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network
2010
Developing a guideline for clinical trial protocol content: Delphi consensus survey
2012
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
Assessing the potential for outcome reporting bias in a review: a tutorial
2010
The extracellular domain of Her2 in serum as a biomarker of breast cancer
2018
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 Standout
John Snow's legacy: epidemiology without borders
2013 StandoutNobel
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study
2012
A Test in Context: Lipoprotein(a)
2017
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Many scenarios exist for selective inclusion and reporting of results in randomized trials and systematic reviews
2013
Guidelines for randomized clinical trial protocol content: a systematic review
2012
Tracking Replicability as a Method of Post-Publication Open Evaluation
2012
Long-term Persistence in Use of Statin Therapy in Elderly Patients
2002
Poverty and common mental disorders in low and middle income countries: A systematic review
2010
Imaging in the era of molecular oncology
2008 StandoutNature
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias — An Updated Review
2013
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
Identification of Additional Trials in Prospective Trial Registers for Cochrane Systematic Reviews
2012
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
2009 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
SYNTHESIS: Cancer research meets evolutionary biology
2009
The changing landscape of atherosclerosis
2021 StandoutNature
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
2012
Avoidable waste in the production and reporting of research evidence
2009
The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews
2010
Bias Due to Changes in Specified Outcomes during the Systematic Review Process
2010
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
The Evolution of a Canadian Hypertension Education Program Recommendation: The Impact of Resistance Training on Resting Blood Pressure in Adults as an Example
2013
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists
2011
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
2010 Standout
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Perceived information gain from randomized trials correlates with publication in high–impact factor journals
2012
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005
2007
The False-positive to False-negative Ratio in Epidemiologic Studies
2011
Global cancer statistics
2011 Standout
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
2008
Guidance for Developers of Health Research Reporting Guidelines
2010
“Positive” Results Increase Down the Hierarchy of the Sciences
2010
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
2011 Standout
Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results
2008
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Raise standards for preclinical cancer research
2012 StandoutNature
Oesophageal carcinoma
2013 Standout
Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols
2008
Avoidable Waste in the Production and Reporting of Research Evidence
2009
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands
2012
Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials
2009
Chronic hepatitis B
2007 Standout
The Importance of Potential Studies That Have Not Existed and Registration of Observational Data Sets
2012
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Reporting bias in medical research - a narrative review
2010
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
2017 Standout
Cardiovascular Disease Risk Factors in Chronic Kidney Disease
2006
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
2012
Long-Term Results of a Phase II Trial of Neoadjuvant Chemotherapy Followed by Esophagectomy for Locally Advanced Esophageal Neoplasm
2008
Probiotic administration can prevent necrotizing enterocolitis in preterm infants: A meta-analysis
2015
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Out of sight but not out of mind: how to search for unpublished clinical trial evidence
2012
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
2015 Standout
Gastric cancer
2020 Standout
Statins, inflammation and kidney disease
2011
Lipid Disorders in Uremia and Dialysis
2012
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
2016
Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles
2011
La pharmacopée de prévention cardiovasculaire est-elle sous-utilisée chez les patients souffrant d’insuffisance rénale chronique après un infarctus du myocarde ?
2010
Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention
2014
Clonal evolution in cancer
2012 StandoutNature
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
2007
Evaluation of Excess Statistical Significance in Meta-analyses of 98 Biomarker Associations with Cancer Risk
2012
Testing for the Presence of Positive-Outcome Bias in Peer Review
2010
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Quantifying Selective Reporting and the Proteus Phenomenon for Multiple Datasets with Similar Bias
2011
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
The ClinicalTrials.gov Results Database — Update and Key Issues
2011
Trends in oesophageal cancer incidence and mortality in Europe
2007
Excess Significance Bias in the Literature on Brain Volume Abnormalities
2011
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
The cancer genome
2009 StandoutNature
Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
2005 Standout
Adherence to Medication
2005 Standout
Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis
2012
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 Standout
Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
2012
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
2010 Standout
Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO
2011
Comparison of protocols and registry entries to published reports for randomised controlled trials
2011
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
2010
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions
2014
Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease
2012
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
2009
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
2007
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
2012
Statins for the primary prevention of cardiovascular disease
2013
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013
A Comprehensive Survey of Ras Mutations in Cancer
2012 Standout
The Importance of Clinical Trial Data Sharing
2012
Cancer Genome Landscapes
2013 StandoutScience
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
2014
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials.
2010
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
2018 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Global cancer statistics, 2012
2015 Standout
Negative results are disappearing from most disciplines and countries
2011
Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review
2011
Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials
2012
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
2009 Standout
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
2009
Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer
2017 Standout
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Industry sponsorship and research outcome
2017 Standout
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
2013 Standout
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
2008
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
2009
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
The Measurement of Observer Agreement for Categorical Data
1977 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
2020
Promoting Transparency in Social Science Research
2014 StandoutScienceNobel
Works of John Simes being referenced
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
2016
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study
2010
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
2015
Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.
2012
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
2010
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
2007
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes
2006
Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction
1995
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
2018
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
2008
Single agent versus combination chemotherapy for metastatic breast cancer
2005
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
2010
Single agent versus combination chemotherapy for metastatic breast cancer
2009
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
2005
Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial
2001
Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer
2015
Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
2011
Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial
2001
INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.
2015
Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
2004
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
2013
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
2016
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
2006
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)
2007